U.S. markets closed
  • S&P Futures

    3,828.00
    +2.50 (+0.07%)
     
  • Dow Futures

    30,959.00
    +26.00 (+0.08%)
     
  • Nasdaq Futures

    11,681.75
    +7.50 (+0.06%)
     
  • Russell 2000 Futures

    1,739.40
    +1.10 (+0.06%)
     
  • Crude Oil

    111.10
    -0.66 (-0.59%)
     
  • Gold

    1,822.00
    +0.80 (+0.04%)
     
  • Silver

    20.78
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0535
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    3.2060
    +0.0120 (+0.38%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2209
    +0.0024 (+0.20%)
     
  • USD/JPY

    136.0640
    -0.0640 (-0.05%)
     
  • BTC-USD

    20,310.88
    -287.21 (-1.39%)
     
  • CMC Crypto 200

    440.19
    -9.87 (-2.19%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,739.65
    -309.82 (-1.15%)
     

MacroGenics to Participate in Upcoming Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
MacroGenics, Inc.
MacroGenics, Inc.

ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in June 2022:

  • The JMP Securities Life Sciences Conference. MacroGenics’ management is scheduled to participate in a fireside chat on Thursday, June 16, 2022, at 12:00 pm ET, and will also participate in one-on-one meetings.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

CONTACT: CONTACTS: Chris James, M.D., Vice President, Investor Relations & Corporate Communications Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com